Medtronic (MDT) Receives FDA 510(k) Clearance for OsteoCool RF Ablation System
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Medtronic Expands Pain Therapies Portfolio with the Launch of OsteoCool(TM) RF Ablation System
January 13, 2016 8:01 AM ESTMinimally-Invasive Procedure Brings Relief to Patients
Suffering from Painful Spine Tumors
DUBLIN - January 13, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and U.S. launch of the OsteoCool(TM) RF Ablation System. For physicians who treat patients with painful spine metastases, the OsteoCool System is the only cooled radiofrequency (RF) ablation technology that... More